Adma Biologics, Inc.
A maker of plasma-derived medicines for people with weakened immune systems, ADMA Biologics produces immune globulin therapies such as BIVIGAM and Nabi-HB, used to treat primary immunodeficiency and to guard against hepatitis B. The company was formed in 2013 when ADMA Biologics merged with Nabi Biologics, combining their plasma collection and manufacturing operations. Headquartered in Boca Raton, Florida, it collects plasma and turns it into treatments for immune deficiency patients.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| STATE STREET CORPORATION | 13GPassive | 7.4% | 17.12M | Aug 7, 2026 |
| SSGA FUNDS MANAGEMENT, INC. | 13GPassive | 5% | 11.59M | Aug 7, 2026 |
| Vanguard Capital Management | 13GPassive | 5.08% | 12.11M | Apr 29, 2026 |
| The Vanguard Group | 13G/APassive | 0% | 0 | Mar 26, 2026 |
| Invesco Ltd. | 13G/APassive | 5% | 11.79M | Feb 12, 2026 |
| BlackRock, Inc. | 13G/APassive | 15.1% | 35.91M | Apr 30, 2025 |